Editas Medicine Inc.

17.34-1.12-6.07%Vol 1.94M1Y Perf -69.23%
Aug 16th, 2022 16:00 DELAYED
BID17.13 ASK18.00
Open18.35 Previous Close18.46
Pre-Market- After-Market17.89
 - -  0.55 3.17%
Target Price
34.20 
Analyst Rating
Hold 2.75
Potential %
97.23 
Finscreener Ranking
★★     46.09
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     49.62
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     48.73
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
12.22 
Earnings Rating
Neutral
Market Cap1.19B 
Earnings Date
3rd Aug 2022
Alpha0.00 Standard Deviation0.26
Beta1.93 

Today's Price Range

16.9218.35

52W Range

9.5973.03

5 Year PE Ratio Range

-12.90-10.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-6.52%
1 Month
15.68%
3 Months
49.10%
6 Months
11.08%
1 Year
-69.23%
3 Years
-32.37%
5 Years
-7.77%
10 Years
-

TickerPriceChg.Chg.%
EDIT17.34-1.1200-6.07
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
ProfitabilityValueIndustryS&P 500US Markets
-
-584.40
-566.00
-466.50
-87.89
RevenueValueIndustryS&P 500US Markets
31.80M
0.46
4.85
34.13
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.84-0.787.14
Q01 2022-0.81-0.748.64
Q04 2021-0.78-0.6121.79
Q03 2021-0.86-0.5733.72
Q02 2021-0.85-0.814.71
Q01 2021-0.76-0.86-13.16
Q04 2020-0.82-1.00-21.95
Q03 2020-0.660.12118.18
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.84-1.20Negative
9/2022 QR-0.880.00-
12/2022 FY-3.41-3.96Negative
12/2023 FY-3.38-3.68Negative
Next Report Date-
Estimated EPS Next Report-0.84
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume1.94M
Shares Outstanding68.74K
Shares Float61.19M
Trades Count20.39K
Dollar Volume33.81M
Avg. Volume1.69M
Avg. Weekly Volume1.68M
Avg. Monthly Volume1.71M
Avg. Quarterly Volume1.67M

Editas Medicine Inc. (NASDAQ: EDIT) stock closed at 17.34 per share at the end of the most recent trading day (a -6.07% change compared to the prior day closing price) with a volume of 1.94M shares and market capitalization of 1.19B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 235 people. Editas Medicine Inc. CEO is Cynthia Collins.

The one-year performance of Editas Medicine Inc. stock is -69.23%, while year-to-date (YTD) performance is -34.69%. EDIT stock has a five-year performance of -7.77%. Its 52-week range is between 9.59 and 73.025, which gives EDIT stock a 52-week price range ratio of 12.22%

Editas Medicine Inc. currently has a PE ratio of -7.00, a price-to-book (PB) ratio of 2.77, a price-to-sale (PS) ratio of 39.90, a price to cashflow ratio of 616.40, a PEG ratio of 2.32, a ROA of -27.60%, a ROC of -33.22% and a ROE of -34.20%. The company’s profit margin is -87.89%, its EBITDA margin is -566.00%, and its revenue ttm is $31.80 Million , which makes it $0.46 revenue per share.

Of the last four earnings reports from Editas Medicine Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.84 for the next earnings report. Editas Medicine Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Editas Medicine Inc. is Hold (2.75), with a target price of $34.2, which is +97.23% compared to the current price. The earnings rating for Editas Medicine Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Editas Medicine Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Editas Medicine Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.94, ATR14 : 1.37, CCI20 : 61.44, Chaikin Money Flow : 0.14, MACD : 1.13, Money Flow Index : 72.34, ROC : 12.56, RSI : 48.38, STOCH (14,3) : 65.91, STOCH RSI : 0.39, UO : 54.59, Williams %R : -34.09), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Editas Medicine Inc. in the last 12-months were: Bruce Eaton (Sold 2 705 shares of value $46 261 ), James C. Mullen (Sold 32 057 shares of value $1 017 012 ), Lisa Anne Michaels (Sold 1 568 shares of value $60 101 ), Mark S. Shearman (Sold 5 145 shares of value $51 745 ), Michelle Robertson (Sold 5 782 shares of value $120 549 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (36.36 %)
5 (45.45 %)
5 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (36.36 %)
3 (27.27 %)
3 (30.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
3 (27.27 %)
3 (27.27 %)
2 (20.00 %)
Summary RatingHold
2.75
Moderate Buy
2.57
Moderate Buy
2.33

Editas Medicine Inc.

Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company only operating segment being developing and commercializing genome editing technology.

CEO: Cynthia Collins

Telephone: +1 617 401-9000

Address: 11 Hurley Street, Cambridge 02141, MA, US

Number of employees: 235

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

62%38%

Bearish Bullish

58%42%

TipRanks News for EDIT

Wed, 03 Aug 2022 23:46 GMT Editas Medicine (EDIT) Gets a Buy Rating from Chardan Capital

- TipRanks. All rights reserved.

Sun, 08 May 2022 15:15 GMT Editas Medicine (EDIT) Gets a Hold Rating from SVB Securities

- TipRanks. All rights reserved.

Fri, 06 May 2022 01:47 GMT Editas Medicine (EDIT) Gets a Hold Rating from RBC Capital

- TipRanks. All rights reserved.

Fri, 06 May 2022 01:16 GMT Editas Medicine (EDIT) Receives a Hold from Barclays

- TipRanks. All rights reserved.

Thu, 05 May 2022 11:45 GMT Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Editas Medicine (EDIT) and Genenta Science SpA Sponsored ADR (GNTA)

- TipRanks. All rights reserved.

Sun, 27 Feb 2022 10:50 GMT Editas Medicine (EDIT) Receives a Hold from RBC Capital

- TipRanks. All rights reserved.

Sat, 26 Feb 2022 16:21 GMT Editas Medicine (EDIT) Gets a Hold Rating from Evercore ISI

- TipRanks. All rights reserved.

Fri, 25 Feb 2022 11:03 GMT Editas Gains 10.1% as Q4 Results Surpass Estimates

- TipRanks. All rights reserved.

Tue, 15 Feb 2022 14:41 GMT Editas Medicine (EDIT) Gets a Hold Rating from Leerink Partners

- TipRanks. All rights reserved.

News

Stocktwits